Jakavi (ruxolitinib): Reviews and patient testimonials


/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Back Back to the list of medications

Medication indications

Jakavi 5mg, 10mg, 15mg and 20mg Tablets

Myelofibrosis (MF)

Jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

Polycythaemia vera (PV)

Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.


Route of administration: Oral
Molecule: ruxolitinib

Patients' opinions on Jakavi

In brief

General satisfaction level: 6.00/10 Learn more

Treatment's effectiveness: 5.00/10 Learn more

Ease of use: 10.00/10 Learn more

Adherence to prescription: 10.00/10 Learn more

Detected side effects: 4.00/10 Learn more

Improvement in the quality of life: 6.00/10 Learn more

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.